IDYA ▼ -4.6% - IDEAYA Biosciences, Inc. $IDYA IDYA - IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas 16-NOV-2026 04:06 PM ET